Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Dolutegravir / abacavir / lamivudine (Triumeq®) is recommended as an option for use within NHS Wales for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised. |
|||
|
|||
Medicine details |
|||
| Medicine name | dolutegravir / abacavir / lamivudine (Triumeq®) | ||
| Formulation | 50 mg / 600 mg / 300 mg film-coated tablet | ||
| Reference number | 2365 | ||
| Indication | Treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg |
||
| Company | ViiV Healthcare UK Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 0415 | ||
| NMG meeting date | 25/02/2015 | ||
| AWMSG meeting date | 25/03/2015 | ||
| Ratification by Welsh Government | 15/05/2015 | ||
| Date of issue | 20/05/2015 | ||
| Date of last review | 27/03/2018 | ||
| Commercial arrangement | WPAS | ||